ER/PR by IHC & Her2neu by FISH

Also referred as

Breast Hormone Receptor Test

Estrogen receptor (ER) Test

Progesterone receptor (PR) Test

Her2/neu Test

c-erb-B2 Test

For men & women

Earliest reports in

168 hours

Contains

1 test

Test price:

₹10450

~~₹11000~~

5% off

Know more about this test

The ER/PR by IHC & Her2neu by FISH test checks for hormone receptors (ER and PR) and the HER2 gene in cancer tissue. It helps doctors understand how the tumor grows and decide on the best treatment, such as hormone therapy for ER/PR-positive cancers or targeted therapy for HER2-positive cases. This test supports personalized treatment planning and better outcomes in breast and other hormone-related cancers.

Samples required

Tissue Block : FFPE ( Formalin-Fixed & Paraffin-Embedded)

Find out

Why is this test booked?

Preparation for this test

Sample Collection

Who will collect your samples?

Test conducted by

Core Diagnostics Private Limited

ISO, CAP, NABL certified

Know More

Know more about lab

Core Diagnostics Private Limited

ISO, CAP, NABL certified

About this lab

We at CORE Diagnostics are a renowned pathology testing laboratory & a premier institute in the country capable of providing varied diagnostic tests & facilities in the field of laboratory medicine and have established state-of-art testing facilities in Gurgaon. We are a Clinical laboratory focused on Next Generation Diagnostics for disease stratification and therapy selection. We are focused on bringing the most advanced testing techniques and expertise to India and aim to become the destination for all your high-end diagnostic needs.

Understanding ER/PR by IHC & Her2neu by FISH

The ER/PR by IHC & Her2neu by FISH test is a combined diagnostic evaluation used to assess the molecular characteristics of breast and certain other cancers.

The Estrogen Receptor (ER) and Progesterone Receptor (PR) status are determined using Immunohistochemistry (IHC), a staining method that detects hormone receptor proteins on the surface of tumor cells.
The HER2/neu gene amplification is detected using Fluorescence In Situ Hybridization (FISH), a genetic test that identifies whether extra copies of the HER2 gene are present in the cancer cells.

Together, these tests help identify whether a tumor is hormone receptor-positive (likely to respond to hormone therapy) or HER2-positive (likely to respond to targeted therapy such as trastuzumab). This combined information allows doctors to plan individualized treatment strategies and predict disease behavior more accurately.

Doctors may recommend the ER/PR by IHC & Her2neu by FISH test for individuals who have been newly diagnosed with breast cancer to determine the hormone receptor status of the tumor. It is also advised for patients with recurrent or metastatic breast cancer to reassess these receptors and guide further treatment. This test helps evaluate how aggressive the cancer is, decide whether hormone therapy or targeted therapy will be effective, and monitor the response to ongoing treatment.

For this test, it is important to provide the clinical history, histopathology report, relevant test reports, and doctor’s prescription at the time of sample collection. A Tata 1mg consolidated Test Requisition Form (TRF) must also be duly filled and submitted along with the sample.

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.

What does ER/PR by IHC & Her2neu by FISH measure?

The ER/PR by IHC & Her2neu by FISH test detects the presence of estrogen receptor (ER), progesterone receptor (PR), and HER2/neu (c-erb-B2) proteins in breast tissue samples. These proteins help determine the hormone receptor status and aggressiveness of breast cancer. The test uses two methods: Immunohistochemistry (IHC) to assess ER and PR expression levels, and Fluorescence In Situ Hybridization (FISH) to evaluate HER2/neu gene amplification.

Understanding the expression or amplification of these markers is crucial for guiding personalized treatment. For example: hormone therapy for ER/PR-positive cancers and targeted therapy (like trastuzumab) for HER2/neu-positive cases.

Test Information is reviewed by: Dr. Swati Gupta (Anand), MBBS, MD Lab Medicine and written by Dr. Lipika Khurana, BDS, PGDHHM . The test details are for information purpose only. Consult a doctor before taking any test. Last updated on: 12th Jul 2026

Did you find information useful ?

YES

ER/PR by IHC & Her2neu by FISH test price for other cities

Price in	Ahmedabad	Rs. 10450
Price in	Allahabad	Rs. 10450
Price in	Asansol	Rs. 10450
Price in	Bangalore	Rs. 10450
Price in	Bhopal	Rs. 10450

Book a Mumps, PCR, Qualitative test at home near me

Easy online booking

Search for tests and packages, book your preferred time slot and enter your address for seamless at-home lab tests.

Live tracking of phlebotomist

Track our trained phlebotomist's real time location for seamless sample collection.

Safe Sample Collection

Our phlebotomists follow strict safety protocols to collect samples safely at home and on time.

Sample received at lab

Samples are transported securely to our accredited labs with world-class machines for testing by qualified experts.

Quick, Doctor-Verified Reports

Get doctor-approved reports via email and WhatsApp, with options for doctor follow-ups and AI insights.

FAQs related to ER/PR by IHC & Her2neu by FISH

What is the ER/PR by IHC & Her2neu by FISH test?

The ER/PR by IHC & Her2neu by FISH test is used to detect specific protein and gene changes in breast cancer tissue. It helps determine whether the cancer cells have estrogen or progesterone receptors (ER/PR) and whether they show amplification of the HER2/neu gene. These findings are important for selecting the most effective treatment options.

Who should get this test done?

Doctors may recommend this test for individuals who have been newly diagnosed with breast cancer, have recurrent or metastatic disease, or need to assess response to ongoing therapy. It is also useful when planning targeted or hormone-based treatments.

Is fasting required before the test?

No, fasting or any special preparation is not required for this test.

Are there any risks involved?

The test is performed on a tissue sample (biopsy or surgical specimen), so there are no additional risks apart from those associated with the biopsy procedure.

What type of sample is required?

A formalin-fixed paraffin-embedded (FFPE) tissue block or unstained slides from the tumor specimen are required. Along with the sample, the clinical history, histopathology report, previous test reports, and doctor’s prescription should be provided. A Tata 1mg consolidated Test Requisition Form (TRF) must also be duly filled and submitted.

What do the test results mean?

ER/PR Positive: The tumor is likely to respond to hormone therapy. ER/PR Negative: Hormone therapy may not be effective. HER2/neu Positive: Indicates eligibility for targeted therapies such as trastuzumab. HER2/neu Negative: Targeted HER2 therapy may not be beneficial.

How often is this test repeated?

This test is usually performed at diagnosis. It may be repeated if the cancer recurs or metastasizes, as receptor status can sometimes change over time.

Need help?